These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31554440)

  • 1. Investigational MET inhibitors to treat Renal cell carcinoma.
    Nandagopal L; Sonpavde GP; Agarwal N
    Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
    Stitzlein L; Rao P; Dudley R
    Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
    Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
    Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tyrosine kinase inhibitors for renal cell carcinoma.
    Dorff TB; Pal SK; Quinn DI
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
    Su D; Singer EA; Srinivasan R
    Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-clear cell advanced kidney cancer: is there a gold standard?
    Sánchez P; Calvo E; Durán I
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
    Sonpavde G; Willey CD; Sudarshan S
    Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
    Iacovelli R; Albiges L; Escudier B
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
    Chen Q; Cheng L; Li Q
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
    [No Abstract]   [Full Text] [Related]  

  • 16. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
    Bilen MA; Carlisle JW; Sonpavde G
    Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
    Reed JP; Posadas EM; Figlin RA
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of renal cell carcinoma: Current status and future directions.
    Barata PC; Rini BI
    CA Cancer J Clin; 2017 Nov; 67(6):507-524. PubMed ID: 28961310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.